News Breaks |
|
|
| October 4, 2012 |
| 09:40 EDT |  | SRPT | Sarepta mentioned cautiously in blog post
In a blog titled "The RNAi Therapeutics Blog," author Dirk Haussecker questioned the quality of the clinical trial data that Sarepta Therapeutics (SRPT) reported yesterday. Haussecker stated, "I am obviously trying to find any shares to short," and "I reserve the right to buy, sell, or short any security including those that may or may not be discussed on my blog." Reference Link |
|
|
News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. |
|
|
| May 16, 2013 |
| 07:29 EDT |  | SRPT | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. |
|
| May 9, 2013 |
| 12:21 EDT | | SRPT | Sarepta climbs after saying documents to be submitted this month
 Subscribe for More Information |
|
| 07:29 EDT |  | SRPT | Sarepta reports Q1 EPS (41c), consensus (62c)
Reports Q1 revenue $4.5M, consensus $5.85M. |
|
| May 7, 2013 |
| 13:15 EDT |  | SRPT | Options with increasing implied volatility: CVRR SRPT PGH TWO GDI HNZ
Subscribe for More Information |
|
| 08:59 EDT | | SRPT | Sarepta initiates dosing in Phase I study of Marburg virus treatment
Subscribe for More Information |
|
|
|
|
|
